Nanoscale Topical Pharmacotherapy in Management of Psoriasis: Contemporary Research and Scope
Source abstract
Abstract
Psoriasis is a typical dermal condition that has been anticipated since prehistoric times when it was mistakenly implicit in being a variant of leprosy. It is an atypical organ-specific autoimmune disorder, which is triggered by the activation of T-cells and/or B-cells. Until now, the pathophysiology of this disease is not completely explicated and still, many research investigations are ongoing. Different approaches have been investigated to treat this dreadful skin disease using various anti-psoriatic drugs of different modes of action through smart drug-delivery systems. Nevertheless, there is no ideal therapy for a complete cure of psoriasis owing to the dearth of an ideal drug-delivery system for anti-psoriatic drugs. The conventional pharmacotherapy approaches for the treatment of psoriasis demand various classes of anti-psoriatic drugs with optimum benefit/risk ratio and insignificant untoward effects. The advancement in nanoscale drug delivery had a great impact on the establishment of a nanomedicine-based therapy for better management of psoriasis in recent times. Nanodrug carriers are exploited to design and develop nanomedicine-based therapy for psoriasis. It has a promising future in the improvement of the therapeutic efficacy of conventional anti-psoriatic drugs. The present manuscript aims to discuss the pathophysiology, conventional pharmacotherapy, and contemporary research in the area of nanoscale topical drug delivery systems for better management of psoriasis including the significance of targeted pharmacotherapy in psoriasis.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Psoriasis: Treatment and Pathogenesis · Advancements in Transdermal Drug Delivery · Dermatology and Skin Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati 781101, Assam, India
Funding
Deanship of Scientific Research at Najran University, Saudi Arabia,
References (100+)
Show source-provided references
1. Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS)10.1016/j.jconrel.2016.07.003 ↗
2. Novel colloidal carriers for psoriasis: Current issues, mechanistic insight and novel delivery approaches10.1016/j.jconrel.2013.05.020 ↗
3. Chemokine receptors in the pathogenesis and therapy of psoriasis10.1016/j.jdermsci.2011.11.007 ↗
4. (2022, October 30). Global Report on Psoriasis. Available online: https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf.psoriasis?sequence=1.
5. Psoriasis10.1016/S0140-6736(14)61909-7 ↗
6. Deep Learning Application for Effective Classification of Different Types of Psoriasis10.1155/2022/7541583 ↗
7. (2022, August 21). Facts and Statistics about Psoriasis. Available online: https://www.healthline.com/health/psoriasis/facts-statistics-infographic.
8. American Academy of Dermatology (2022, November 01). Psoriasis Resource Center. Available online: https://www.aad.org/public/diseases/scaly-skin/psoriasis.
9. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics10.1016/j.jaad.2008.02.039 ↗
10. The role of drugs in the induction and/or exacerbation of psoriasis10.1111/j.1365-4632.2010.04570.x ↗
11. Epidemiology and clinical pattern of psoriatic arthritis in Germany: A prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis10.1111/j.1365-2133.2008.09023.x ↗
12. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis10.1159/000083509 ↗
13. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study)10.1111/bjd.12190 ↗
14. Connective tissue diseases and psoriasis10.1016/j.ad.2011.03.002 ↗
15. The immunopathogenesis of psoriasis10.1016/j.det.2014.09.002 ↗
16. Immunopathogenesis of psoriasis10.1007/s12016-007-0039-2 ↗
17. Psoriasis pathophysiology: Current concepts of pathogenesis10.1136/ard.2004.031120 ↗
18. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses10.1016/j.it.2012.11.005 ↗
19. Expression of vascular endothelial growth factor in normal epidermis, epithelial tumors and cultured keratinocytes10.1007/s004030050172 ↗
20. Human keratinocytes are a major source of cutaneous platelet-derived growth factor10.1172/JCI116636 ↗
21. Pathogenesis and therapy of psoriasis10.1038/nature05663 ↗
22. Getting under the skin: The immunogenetics of psoriasis10.1038/nri1689 ↗
23. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)10.1073/pnas.0509736102 ↗
24. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris10.1084/jem.20030451 ↗
25. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects10.1038/sj.jid.5700310 ↗
26. The immunologic basis for the treatment of psoriasis with new biologic agents10.1067/mjd.2002.120568 ↗
27. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production10.1084/jem.20050500 ↗
28. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-2210.1038/jid.2012.456 ↗
29. Modulation of keratinocyte-derived MMP-9 by IL-13: A possible role for the pathogenesis of epidermal inflammation10.1038/sj.jid.5700940 ↗
30. IL-13-stimulated human keratinocytes preferentially attract CD4+CCR4+ T cells: Possible role in atopic dermatitis10.1038/sj.jid.5700085 ↗
31. Cyclosporine and tacrolimus in dermatology10.1016/S0733-8635(05)70234-5 ↗
32. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients10.1111/j.1365-2125.2007.02888.x ↗
33. Pimecrolimus (Elidel, SDZ ASM 981)—Preclinical pharmacologic profile and skin selectivity10.1053/sder.2001.29066 ↗
34. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies10.1016/j.jaad.2008.12.032 ↗
35. Current concepts in psoriasis and its treatment10.1016/S0163-7258(03)00041-X ↗
36. Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis10.1016/j.steroids.2015.05.012 ↗
37. Treatment of psoriasis with calcipotriol and other vitamin D analogues10.1016/0190-9622(92)70302-V ↗
38. Emollients, moisturizers, and keratolytic agents in psoriasis10.1016/j.clindermatol.2008.01.015 ↗
39. Topical psoriasis therapy
40. “Keratolytic” effect of salicylic acid10.1007/BF00741846 ↗
41. Urea in dermatology I
42. Halobetasol versus clobetasol: A study of potency10.4103/0378-6323.48672 ↗
43. Calcipotriol/betamethasone dipropionate: A review of its use in the treatment of psoriasis vulgaris10.2165/00128071-200405060-00012 ↗
44. Clobetasol propionate foam in the treatment of psoriasis10.1517/14656566.6.10.1735 ↗
45. New topical treatments for psoriasis10.1517/14656566.2014.875159 ↗
46. Topical treatment of psoriasis10.1517/14656566.2010.492778 ↗
47. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate10.1016/S0149-2918(01)80113-2 ↗
48. Fluocinolone acetonide topical oil for scalp psoriasis10.1080/09546630410023566 ↗
49. Physician and Patient Assessment of Triamcinolone Acetonide Spray for Steroid-responsive Dermatoses
50. Efficacy and safety of the Betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: A randomized, parallel-group, active-controlled, phase III study10.2165/11539780-000000000-00000 ↗
51. OncoSec (2022, October 30). What Is Combination Therapy?. Available online: https://oncosec.com/2013/09/what-is-combination-therapy/.
52. Combination therapy to treat moderate to severe psoriasis10.1016/j.jaad.2002.12.002 ↗
53. Therapeutic strategies: Rotational therapy and combinations10.1046/j.1365-2230.2001.00829.x ↗
54. Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, 7–9 October 199410.1016/S0190-9622(96)80148-4 ↗
55. An approach to the treatment of moderate to severe psoriasis with rotational therapy10.1016/0190-9622(93)70067-4 ↗
56. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: A randomised, double-blind trial10.1159/000080854 ↗
57. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis10.1067/mjd.2003.130 ↗
58. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the topical therapy of psoriasis vulgaris: A multicentre, double-blind, randomized study10.1046/j.1365-2133.1998.02070.x ↗
59. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis10.1111/j.1468-3083.1998.tb00948.x ↗
60. Combination of calcipotriol and clobetasol propionate as a premixed ointment for the treatment of psoriasis
61. Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis10.1080/00015550050500022 ↗
62. The efficacy of calcipotriol + acitretin combination therapy for psoriasis: Comparison with acitretin monotherapy10.2165/00128071-200304070-00006 ↗
63. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis10.1046/j.1365-2133.1998.02030.x ↗
64. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: Results of a multicenter placebo-controlled study10.1016/S0190-9622(94)70138-5 ↗
65. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: Results of a multicentre placebo-controlled randomized trial10.1046/j.1365-2133.2003.05173.x ↗
66. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis10.1016/j.jaad.2009.10.016 ↗
67. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis10.1016/S0149-2918(00)83065-9 ↗
68. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis10.1177/120347540200600201 ↗
69. Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris10.1111/j.1468-3083.2009.03214.x ↗
70. Combined treatment of psoriasis with a new aromatic retinoid (Tigason) in low dosage orally and triamcinolone acetonide cream topically: A double-blind trial10.1111/j.1365-2133.1980.tb05693.x ↗
71. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: The BELIEVE study10.1111/j.1365-2133.2010.09791.x ↗
72. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone10.1016/0190-9622(91)70089-K ↗
73. A clinical evaluation of the effects of an aromatic retinoid (Tigason), combination of retinoid and PUVA, and PUVA alone in severe psoriasis10.1111/j.1365-2133.1981.tb00957.x ↗
74. A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re-TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients10.1111/j.1365-2133.1992.tb14815.x ↗
75. Methotrexate/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis—A randomized single-blinded placebo-controlled study10.1111/j.1468-3083.2009.03486.x ↗
76. Calcipotriol monotherapy versus calcipotriol plus UVA1 versus calcipotriol plus narrow-band UVB in the treatment of psoriasis
77. A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris10.1080/09546630410023322 ↗
78. The role of narrowband UV-B plus alefacept combination therapy in the treatment of psoriasis10.1001/archderm.144.8.1067 ↗
79. Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: Results of a comparative study10.1046/j.1365-2133.2001.04074.x ↗
80. Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: A prospective randomized placebo-controlled clinical trial10.1046/j.1365-2133.2003.05380.x ↗
81. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: A safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group10.1159/000018309 ↗
82. Percutaneous absorption and delivery systems310.1016/S0738-081X(01)00183-3 ↗
83. Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors10.4103/0378-6323.72451 ↗
84. Liposomal fusidic acid as a potential delivery system: A new paradigm in the treatment of chronic plaque psoriasis10.3109/10717544.2015.1110845 ↗
85. Influence of formulation factors on the deposition of liposomal components into the different strata of the skin
86. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis10.1016/j.ejps.2016.10.025 ↗
87. Comparison of ethosomes and liposomes for skin delivery of psoralen for psoriasis therapy10.1016/j.ijpharm.2014.06.001 ↗
88. An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: Proof-of-concept in the treatment of psoriasis10.1016/j.ijpharm.2016.01.042 ↗
89. Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome10.1002/jgm.1459 ↗
90. Deformable liposomes for dermal administration of methotrexate10.1016/j.ijpharm.2003.10.006 ↗
91. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment10.1016/j.ijpharm.2012.01.045 ↗
92. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes10.1016/j.jconrel.2007.08.005 ↗
93. Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: Experimental studies in a murine model10.1046/j.1365-2133.2002.04800.x ↗
94. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol10.1016/S0378-5173(01)00810-9 ↗
95. A novelliposomal formulation of dithranol for psoriasis: Preliminary results10.1111/j.1346-8138.2002.tb00321.x ↗
96. Calcipotriol delivery into the skin with PEGylated liposomes10.1016/j.ejpb.2012.04.005 ↗
97. Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis10.1016/j.nano.2017.06.009 ↗
98. Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis10.1080/08982104.2019.1593449 ↗
99. Flexible liposomal gel dual-loaded with all-trans retinoic acid and betamethasone for enhanced therapeutic efficiency of psoriasis10.1186/s12951-020-00635-0 ↗
100. Enhanced penetration and improved therapeutic efficacy of bexarotene via topical liposomal gel in imiquimod induced psoriatic plaque model in BALB/c mice10.1016/j.jddst.2020.101691 ↗